Genetic Technologies appoints Lewis J. Stuart as General Manager of its New North American Molecular Diagnostics Business

06-23-2010: Genetic Technologies Limited announced the appointment of Mr. Lewis Stuart as General Manager of its North American molecular diagnostics business. The new division is the result of the Company’s recent acquisition of US assets including BREVAGen™, a fully validated risk assessment test for non-hereditary breast cancer.

Mr. Stuart brings more than 28 years of US and European health sector sales and marketing experience across multiple therapeutic categories including women’s health, infectious disease and endocrinology.

Mr. Stuart most recently served as Senior Vice President, Commercial Operations at cardiovascular drug developer CV Therapeutics, where he led the launch of Ranexa™ and played a significant role in growing CVT’s market cap from $300 million to its $1.5 billion acquisition by Gilead. In this role, Mr. Stuart had responsibility for sales, marketing, medical affairs, managed care and investor relations. During his tenure at CVT, Mr. Stuart recruited and deployed the company’s 325 person sales team, created the related infrastructure and built a strong foundation for the successful launch of the first in class Ranexa™ franchise in the US and Europe.

Prior to CVT, Mr. Stuart held senior US and European sales and marketing positions within the biotechnology sector, including six years as Vice President, Sales at Agouron Pharmaceuticals, Inc., a Pfizer company. There, he deployed an HIV sales organisation to launch Agouron’s lead product, Viracept, which became the most widely prescribed protease inhibitor in the US and was recognised as biotech’s most successful product launch (Fortune, February 1997). Earlier in Mr. Stuart’s career, he directed the sales teams for several cardiovascular products at Bristol Myers Squibb, Inc. and has also held senior sales and marketing positions with Solvay Pharmaceuticals, Centocor and Upjohn.